| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Disintegrin and metalloproteinase domain-containing protein 10;ADAM 10;3.4.24.81;CDw156;Kuzbanian protein homolog;Mammalian disintegrin-metalloprotease;CD156c;ADAM10;KUZ, MADM; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Form | Liquid |
| Gene ID | |
| Host | |
| Immunogen | A synthesized peptide derived from human HLA-Drb1 Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Storage | |
| Target | |
| UniProt # |
Overview
This product is an anti-HLA-DRB1 antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone AFGA-8; isotype Rabbit IgG; reactivity: Human. Reported application contexts include WB, IHC, ICC, IF (as provided in the source record). Boster Bio Anti-HLA-Drb1 Monoclonal Antibody catalog # M00568-1. Tested in WB, IHC, ICC/IF applications. This antibody reacts with Human.
Key elements and design rationale
- Target: HLA-DRB1 (Disintegrin and metalloproteinase domain-containing protein 10).
- Antibody format: Monoclonal; clone AFGA-8; isotype Rabbit IgG.
- Host: Rabbit.
- Species reactivity: Human (confirm in your model system with appropriate controls).
This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.
Biological background
HLA-DRB1 (protein: T-cell surface glycoprotein CD4) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Cleaves the membrane-bound precursor of TNF-alpha at '76-Ala-|-Val-77' to its mature soluble form. Responsible for the proteolytical release of soluble JAM3 from endothelial cells surface. Responsible for the proteolytic release of several other cell-surface proteins, including heparin-binding epidermal growth- like factor, ephrin-A2 and for constitutive and regulated alpha- secretase cleavage of amyloid precursor protein (APP). Contributes to the normal cleavage of the cellular prion protein. Involved in the cleavage of the adhesion molecule L1 at the cell surface and in released membrane vesicles, suggesting a vesicle-based protease activity. Controls also the proteolytic processing of Notch and mediates lateral inhibition during neurogenesis. Responsible for the FasL ectodomain shedding and for the generation of the remnant ADAM10-processed FasL (FasL APL) transmembrane form. Also cleaves the ectodomain of the integral membrane proteins CORIN and ITM2B. May regulate the EFNA5-EPHA3 signaling. . Reported cellular localization context: Cell membrane; Single-pass type I membrane protein. Endomembrane system; Single-pass type I membrane protein. Is localized in the plasma membrane but is predominantly expressed in the Golgi apparatus and in released membrane vesicles derived likely from the Golgi. Tissue expression notes (as provided): Expressed in spleen, lymph node, thymus, peripheral blood leukocyte, bone marrow, cartilage, chondrocytes and fetal liver. .
Research relevance and current trends
- Research context keywords from the source record include: Adaptive Immunity,Immunology.
- Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
- Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.
Common research applications
- Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
- Immunohistochemistry (IHC): evaluate spatial distribution of target-positive staining in tissue architecture.
- Immunofluorescence/ICC (IF/ICC): visualize subcellular localization patterns and cell-to-cell heterogeneity.
Workflow ideas (metafield): Validate HLA-DRB1 antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect HLA-DRB1 expression by Western blot in cell or tissue lysates, Detect HLA-DRB1 in FFPE tissue sections by immunohistochemistry, Localize HLA-DRB1 by immunofluorescence/immunocytochemistry in cultured cells
Notes for experimental interpretation
- Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
- Apparent molecular weight may vary by sample type and processing (observed MW: 272 kDa; calculated MW: 84142 MW).
- Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.
Additional product details (from the source record)
- Molecular weight (observed): 272 kDa
- Cellular localization (provided): Cell membrane; Single-pass type I membrane protein. Endomembrane system; Single-pass type I membrane protein. Is localized in the plasma membrane but is predominantly expressed in the Golgi apparatus and in released membrane vesicles derived likely from the Golgi.
- Tissue details (provided): Expressed in spleen, lymph node, thymus, peripheral blood leukocyte, bone marrow, cartilage, chondrocytes and fetal liver. .
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
